证券日报网讯 2月4日，大北农发布公告称，公司沉痛公告，公司实际控制人、董事长邵根伙先生于 2026年2月3日因病逝世，享年60岁。公司各位董事、高级管理人员及全体员工对邵根伙先生的逝世表示 深切哀悼和缅怀！邵根伙先生持有的公司股份将按照法律、法规办理相关手续，公司将及时履行信息披 露义务。邵根伙先生逝世后，公司现任董事人数由9人减少至8人，不会导致公司董事会成员低于法定最 低人数。根据《公司章程》的规定，由公司副董事长张立忠先生代行董事长职责，直至公司董事会选举 新任董事长为止。目前，公司董事会、高级管理人员正常履职，公司各项经营业务正常开展。 （编辑 任世碧） ...

证券日报网讯 2月4日，凯旺科技发布公告称，公司股票连续三个交易日（2026年2月2日、2026年2月3 日、2026年2月4日）收盘价格涨幅偏离值累计超过30%。根据《深圳证券交易所交易规则》的有关规 定，属于股票异常波动的情况。公司董事会确认，公司目前没有任何根据《深圳证券交易所创业板股票 上市规则》等有关规定应予以披露而未披露的事项；董事会也未获悉公司有根据《深圳证券交易所创业 板股票上市规则》等有关规定应予以披露而未披露的、对公司股票价格产生较大影响的信息；公司及董 事会全体成员保证前期公告内容真实、准确、完整，没有虚假记载、误导性陈述或重大遗漏。 （编辑 袁冠琳） ...

（编辑 任世碧） 证券日报网讯 2月4日，广东建工发布公告称，2026年2月3日，公司的全资子公司广东省第四建筑工程 有限公司（简称"广东四建"）收到深圳市弘铭项目管理有限公司发来的《中标通知书》。该《中标通知 书》确定广东四建与中联合创设计有限公司组成的联合体为"年产2GWh三维固态锂电池智能制造（江 西余干）生产基地项目【项目编号：HMZB-251127】"的中标单位，中标金额为152，437.5438万元，最 终金额以实际签订合同为准。 ...

Group 1 - The core point of the article is that Xingfa Group announced that investors holding convertible bonds can either continue trading in the secondary market or convert at a price of 28.40 yuan per share, otherwise they will face forced redemption at a price of 100 yuan per bond plus accrued interest of 0.6699 yuan per bond, totaling 100.6699 yuan per bond, which may lead to significant investment losses [1] Group 2 - The announcement highlights the limited options available to investors regarding their convertible bonds, emphasizing the potential for substantial financial loss if forced redemption occurs [1] - The specific terms of the forced redemption include a face value of 100 yuan per bond and accrued interest, indicating the financial implications for investors [1] - The situation underscores the importance of monitoring market conditions and the performance of convertible bonds for investors in the sector [1]

Core Viewpoint - The company, Fuhua, announced that it has completed the registration of two new raw materials, "Feruloyl Tripeptide-129 Amide" and "Acetyl Tyrosyl Cyclo D-Glutamyl Tripeptide-110 Amide," which are expected to enhance its product matrix by enabling further product development [1] Group 1 - The company plans to develop products based on the newly registered raw materials [1] - The registration of the new raw materials is expected to be completed by 2025 [1] - Detailed information regarding the raw material registration can be found on the National Medical Products Administration website [1]

Group 1 - The company emphasizes the importance of market value management and maintaining investor interests as a state-owned enterprise [1] - The company plans to enhance daily operations and future strategic planning while improving communication with market participants [1] - The company aims to continuously improve the quality of information disclosure and strengthen investor relations management to enhance company value and return to shareholders [1] Group 2 - The stock price in the secondary market is influenced by various complex factors, including macroeconomic conditions, industry trends, market sentiment, and investor preferences, leading to uncertainty [1]

Core Viewpoint - The company, Fuhua, is enhancing its research and development capabilities through a dual-center approach in Shanghai and Harbin, focusing on raw material development and medical device product research respectively [1] Group 1: Research and Development Strategy - The Shanghai R&D center is dedicated to raw material development and the application of cutting-edge technologies [1] - The Harbin R&D center specializes in the development of medical device products [1] - The company employs a coordinated internal and external research model, collaborating with third-party research institutions to expand diverse research directions [1] Group 2: Innovation and Competitiveness - The collaborative research focuses on efficacy validation and the application of new raw materials [1] - This internal-external synergy aims to enhance the R&D framework, balancing the autonomy and agility of technological innovation [1] - The strategy is designed to support product iteration and build long-term technological competitiveness [1]

Core Viewpoint - The company has received approval for four Class II medical device registration certificates, indicating progress in its product development and regulatory compliance [1] Group 1 - The company has obtained approval for four medical device registration certificates [1] - The approved products include: medical sodium hyaluronate repair patch, medical sodium hyaluronate repair solution, medical recombinant type III humanized collagen patch, and medical trehalose repair patch [1]

Core Viewpoint - The company is advancing in the low-altitude economy by developing products and applying technology across multiple dimensions, focusing on a "low-altitude operation platform + AI brain" core architecture [1] Group 1: Product Development and Applications - The company has successfully empowered various practical business scenarios such as rail transit inspection, comprehensive government affairs, and river management, receiving widespread recognition and praise from users in these fields [1] - The company is increasing its efforts in closed-space application scenarios and drone development, with a closed-space inspection drone having completed core technology validation [1] Group 2: Future Plans and Progress - The company will continue to accelerate the transformation of technological achievements and steadily promote the launch of new products, with specific progress to be disclosed through official company information [1]

Core Viewpoint - The company, Jin Xin Nong, announced the release of a portion of shares held by its controlling shareholder, Guangzhou Jin Nong Industrial Investment Partnership (Limited Partnership) [1] Group 1 - The controlling shareholder notified the company about the release of share pledges [1] - A total of 25 million shares were released from pledge [1]